Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dosing, Dose-Escalating Phase 1b Study to Evaluate the Safety, PK, PD and Immunogenicity of N-Rephasin® SAL200 After Continuous IV Infusion in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tonabacase (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections
- Focus Adverse reactions
- Sponsors iNtRON Biotechnology
- 28 Jan 2021 Status changed from recruiting to completed.
- 28 Feb 2018 New trial record